Total annualised sales of Eylea & Eylea HD are $11B USD (based on Q3 reporting from Regeneron and Bayer). What would they pay for a product that increased BVCA by 50% and provided lengthened IP protection. Six months sales would be $5.5B. Is that enough to buy Opthea? NB i'm assuming 4 plus letter gain.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable